Protara Therapeutics (NASDAQ:TARA) Insider Jacqueline Zummo Sells 22,598 Shares of Stock

Protara Therapeutics, Inc. (NASDAQ:TARA) insider Jacqueline Zummo sold 22,598 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $5.26, for a total value of $118,865.48. Following the transaction, the insider owned 95,961 shares of the company’s stock, valued at approximately $504,754.86. This trade represents a 19.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Protara Therapeutics Trading Up 1.4%

Shares of Protara Therapeutics stock opened at $5.11 on Friday. Protara Therapeutics, Inc. has a 1 year low of $2.77 and a 1 year high of $7.82. The company’s fifty day simple moving average is $6.05 and its 200-day simple moving average is $5.56. The company has a market cap of $276.35 million, a price-to-earnings ratio of -3.87 and a beta of 1.50.

Protara Therapeutics (NASDAQ:TARA) last released its earnings results on Tuesday, March 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.03). As a group, research analysts forecast that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current fiscal year.

Institutional Trading of Protara Therapeutics

Several institutional investors have recently made changes to their positions in the business. Rhumbline Advisers increased its stake in Protara Therapeutics by 8.2% in the third quarter. Rhumbline Advisers now owns 34,137 shares of the company’s stock valued at $148,000 after acquiring an additional 2,596 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Protara Therapeutics by 26.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,736 shares of the company’s stock worth $111,000 after purchasing an additional 4,383 shares during the period. Two Sigma Investments LP boosted its holdings in Protara Therapeutics by 35.8% during the third quarter. Two Sigma Investments LP now owns 19,558 shares of the company’s stock valued at $85,000 after purchasing an additional 5,154 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Protara Therapeutics by 7.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 102,499 shares of the company’s stock valued at $546,000 after purchasing an additional 6,725 shares in the last quarter. Finally, Quadrature Capital Ltd grew its stake in shares of Protara Therapeutics by 39.4% in the 4th quarter. Quadrature Capital Ltd now owns 24,184 shares of the company’s stock valued at $129,000 after purchasing an additional 6,838 shares during the period. 38.13% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. assumed coverage on shares of Protara Therapeutics in a research note on Wednesday, March 4th. They issued an “overweight” rating and a $27.00 target price for the company. TD Cowen restated a “buy” rating on shares of Protara Therapeutics in a research note on Tuesday, March 10th. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price target on shares of Protara Therapeutics in a report on Tuesday, February 10th. Piper Sandler started coverage on Protara Therapeutics in a research report on Wednesday, January 7th. They issued an “overweight” rating and a $24.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Protara Therapeutics in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $21.40.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.